Overexpression of amplified genes is often associated with the acquisition of resistance to cancer therapeutic agents in vitro. We have identified a similar molecular mechanism in vivo for endocrine treatment failure in human prostate cancer which involves amplification of the androgen receptor (AR) gene. Comparative genomic hybridization shows that amplification of the Xq11–q13 region (the location), is common in tumours recurring during androgen deprivation therapy. We found high–level AR amplification in seven of 23 (30%) recurrent tumours, but in none of the specimens taken from the same patients prior to therapy. Our results suggest that AR amplification emerges during androgen deprivation therapy by facilitating tumour cell growth in low androgen concentrations.
Subscribe to Journal
Get full journal access for 1 year
only $17.42 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Boring, C.C., Squires, T.S. & Tong, T. Cancer Statistics, 1993 CA. Cancer J. Clin. 43, 7–26 (1993).
Gittes, R.F. Carcinoma of the prostate. New Engl. J. Med. 324, 236–245 (1991).
Stearn, M.E. & McGarvey, T. Biology of disease. Prostate cancer: therapeutics, diagnostic, and basic studies. Lab. Invest. 67, 540–552 (1992).
Berges, R.R., Furuya, Y., Remington, L., English, H.F., Jacks, T. .& Isaacs, J.T. Cell proliferation, DNA repair, and p53 function are not required for programmed death of prostatic glandular cells induced by androgen ablation. Proc. natn. Acad. Sci. U.S.A. 90, 8910–8914 (1993).
Labrie, F., Belanger, A., Dupont, A., Luu-The, V., Simard, J. & Labrie, C. Science behind total androgen blockade: from gene to combination therapy. Clin. Invest. Med. 16, 475–492 (1993).
Culig, Z. et al. Mutant androgen receptor detected in an advanced-stage prostatic carcinoma is activated by adrenal androgens and progesterone. Molec. Endocrinol. 7, 1541–1550 (1993).
Schoenberg, M.P. et al. Microsatelllte mutation (CAG24–18) in the androgen receptor gene In human prostate cancer. Biochem. Biophys. Res. Comm. 198, 74–80 (1994).
Veldscholte, J. et al. A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens. Biochem. Biophys. Res. Commun. 173, 534–540 (1990).
Thompson, T.C. Growth factors and oncogenes in prostate cancer. Cancer Cells 2, 345–354 (1990).
Kallioniemi, A. et al. Comparative genomic hybridization for molecular cytogenetic analysis of solid tumours. Science 258, 818–821 (1992).
Kallioniemi, O.-P. et al. Optimizing comparative genomic hybridization for analysis of DNA sequence copy number changes in solid tumours. Genes Chrom. Cancer 10, 231–243 (1994).
Lafreniere, R.G. et al. Physical mapping of 60 DNA markers in the p21.1–21.3 region of the human X chromosome. Genomics 11, 352–363 (1991).
Gaddipati, J.P., McLeod, D.G. & Heidenberg, H.B. Frequent detection of codon 877 mutation in the androgen receptor gene in advanced prostate cancers. Cancer Res. 54, 2861–2864 (1994).
Kellens, R.E. Gene amplificatlon in mammalian cells. A comprehensive guide. (Marcel Dekker, Inc., New York, 1993).
Nowell, P.C. Mechanisms of tumour progression. Cancer Res. 46, 2203–2207 (1986).
Dennis, L. Role of maximal androgen blockade in advanced prostate cancer. Prostate (suppl) 5, 17–22 (1994).
Crawford, E.D. et al. A controlled trial of leuprolide with and without flutamlde in prostatic carcinoma. New Engl. J. Med. 321, 419–424 (1989).
Corvi, R., Amler, L.C., Savelyeva, L., Gehring, M. & Schwab, M. MYCN is retained in single copy at chromosome 2 band p23–p24 during amplification in human neuroblastoma cells. Proc. natn. Acad. Sci. U.S.A. 91, 5523–5527 (1994).
Visakorpi, T. et al. Genetic changes in primary and recurrent prostate cancer by comparative genomic hybridization. Cancer Res. 55, 342–347 (1995).
Cher, M.L., MacGrogan, D., Bookstein, R., Brown, J.A., Jenkins, R.B. & Jensen, R. Comparative genomic hybridization, allelic imbalance, and fluorescence in situ hybridization on chromosome 8 in prostate cancer. Genes Chrom. Cancer 11, 153–162 (1994).
Tanner, M. et al. Increased copy number at 20q13 in breast cancer: defining the minimal region and exclusion of candidate genes. Cancer Res. 54, 2457–2460 (1994).
Sambrook, J., Fritsch, E.F. & Maniatis, T. Molecular Cloning: A Laboratory Manual (Cold Spring Habor Laboratory Press, Cold Spring Harbor, (1989).
Hyytinen, E., Visakorpi, T., Kallioniemi, A., Kallioniemi, O.-P. & Isola, J. Improved technique for analysis of formalin-fixed paraffin-embedded tumours by fluorescence in situ hybridization. Cytometry 16, 93–99 (1994).
Kallioniemi, O.P. et al. ERBB2 amplification in breast cancer analyzed by fluorescence in situ hybridization. Proc. natn. Acad. Sci. U.S.A. 88, 5321–5325 (1992).
Ihalainen, J., Siitari, H., Laine, S., Syvänen, A.C. & Palotie, A. Towards automatic detection of point mutations: use of scintillating microplates in solid-phase minisequencing. Biotechniques 16, 938–943 (1994).
Dixon, W.J. BMDP Statistical Software (University of California Press, Los Angeles, 1981).
Sandberg, A.A. Chromosomal abnormalities and related events in prostate cancer. Hum. Pathol. 23, 368–380 (1992).
Rinker-Schaeffer, C.W. et al. Differential suppression of mammary and prostate cancer metastasis by human chromosomes 17 and 11. Cancer Res. 54, 6249–6256 (1994).
Isaacs, W.B., Bova, G.S., Morton, R.A., Bussemakers, M.J.G., Brooks, J.D. & Ewing, C.M. Molecular biology of prostate cancer. Semin. Oncol. 21, 514–521 (1994).
Macoska, J.A., Micale, M.A., Sakr, W.A., Benson, P.D. & Wolman, S.R. Extensive genetic alterations in prostate cancer revealed by dual PCR and FISH analysis. Genes Chrom. Cancer 8, 88–97 (1993).
About this article
Cite this article
Visakorpi, T., Hyytinen, E., Koivisto, P. et al. In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nat Genet 9, 401–406 (1995). https://doi.org/10.1038/ng0495-401
Androgen Receptor Splice Variant, AR-V7, as a Biomarker of Resistance to Androgen Axis-Targeted Therapies in Advanced Prostate Cancer
Clinical Genitourinary Cancer (2020)
Engineering Prostate Cancer from Induced Pluripotent Stem Cells—New Opportunities to Develop Preclinical Tools in Prostate and Prostate Cancer Studies
International Journal of Molecular Sciences (2020)
Design, Synthesis, and Biological Evaluation of Proteolysis Targeting Chimeras (PROTACs) for the Dual Degradation of IGF-1R and Src
World Journal of Urology (2020)
Molecular Aspects of Medicine (2020)